Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B

Liver Transplantation

Volumn 19, Issue 8, 2013, Pages 887-895

  Perrillo, Robert ^a   Buti, Maria ^b   Durand, Francois ^c   Charlton, Michael ^d   Gadano, Adrian ^e   Cantisani, Guido ^f,g   Loong, Che Chuan ^h   Brown, Kimberly ⁱ   Hu, Wenhua ⁱ   Lopez Talavera, Juan Carlos ⁱ   Llamoso, Cyril ⁱ  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d MAYO CLINIC   (United States)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f Santa Casa Complexo Hospitalar   (Brazil)

^g FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ACUTE KIDNEY FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CHRONIC HEPATITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT INFECTION; HEPATIC ARTERY THROMBOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATOBILIARY DISEASE; HUMAN; IMMUNOTHERAPY; LIMIT OF DETECTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REINFECTION; SEPTIC SHOCK; SEROCONVERSION; SURGICAL MORTALITY;

EID: 84881118150     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23690     Document Type: Article

References (34)

1. Maddrey WC,. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366.
2. Terrault N, Roche B, Samuel D,. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716-732.
3. Katz LH, Paul M, Guy DG, Tur-Kaspa R,. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
4. McCaughan GW,. Prevention of post liver transplant HBV recurrence. Hepatol Int 2011; 5: 876-881.
5. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al.; for Lamivudine North American Transplant Group. A multicenter United States-Canadian Trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432.
6. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722.
7. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.
8. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int 2011; 5: 654-663.
9. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734.
10. Neau-Cransac M, Morel D, Bernard PH, Merville P, Revel P, Potaux L, Saric J,. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16: 368-373.
11. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al.; for BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
12. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
13. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
14. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-79.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al.; for BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
16. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL,. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-1271.
17. Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11: 361-368.
18. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
19. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
20. Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH,. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012; 26: 208-215.
21. Ueda Y, Marusawa H, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013; 43: 67-71.
22. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817.
23. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS,. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381.
24. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
25. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190.
26. Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, et al. Substitution of tenofovir/emtricitabine for hepatitis B immune globulin prevents recurrence of hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145.
27. Lange CM, Sprinzl K, Vermerhren J, Zeuzem S, Sarrazin C,. Prospective study of lactate concentrations in the blood of patients with chronic hepatitis B and decompensated cirrhosis during therapy with a nucleos(t)ide analogue [in German]. Med Klin 2010; 105 (suppl 1): PS-25.
28. Marzano A, Marengo A, Marietti M, Rizzetto M,. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Dis Sci 2011; 43: 1027-1028.
29. Cohen SM, Levy RM, Jovanovich JF, Ahn J,. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009; 43: 1008-1010.
30. Couto CA, Bittencourt PL, Farias AQ, Lallee MP, Cançado EL, Massarollo PC, Mies S,. Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2001; 43: 335-337.
31. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
32. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS Jr, et al.; for NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833.
33. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-815.
34. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW,; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.